Alcon Announces FDA Approval of ... one drop per eye, two times a day. 3 Alcon expects to launch TRYPTYR in the U.S. in the third quarter of 2025 and anticipates bringing TRYPTYR to other ...

Alcon, the global leader in eye care, offers a broad portfolio of products to enhance sight and improve lives for patients in more than 140 countries. Under this arrangement, ...

Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.

Alcon has inked a deal to acquire LumiThera and its light-based therapy for dry age-related macular degeneration, which ...

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living ...

Alcon Inc.’s ALC UNITY Vitreoretinal Cataract System (“VCS”) has recently received approval from Health Canada. UNITY VCS is ...

Alcon AG plans to acquire Lumithera Inc., adding its photobiomodulation (PBM) device designed to treat early and intermediate ...

On Dec. 21, Alcon Laboratories issued a voluntary recall of one lot of its Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25-count (Lot 10101) after a consumer complaint revealed ...

TRYPTYR® (acoltremon ophthalmic solution) 0.003% logo. Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. Food and Drug ...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. Food and Drug Administration (FDA) has approved TRYPTYR ® (acoltremon ...